Evidence map›Paper›PMID 36231893›Full record

ArticleInternational journal of environmental research and public health2022

Moderate, Little, or No Improvements in Neurobehavioral Symptoms among Individuals with Long COVID: A 34-Country Retrospective Study.

Daniela Ramos-Usuga, Paul B Perrin, Yelena Bogdanova, Laiene Olabarrieta-Landa, Elisabet Alzueta, Fiona C Baker, Stella Iacovides, Mar Cortes, Juan Carlos Arango-Lasprilla

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 3 countries.

Daniela Ramos-UsugaBiomedical Research Doctorate Program, University of the Basque Country, Barrio Sarriena, s/n, 48940 Leioa, Spain.
Paul B PerrinDepartment of Psychology, School of Data Science, University of Virginia, 400 Brandon Ave., #177, Charlottesville, VA 22903, USA.ORCID 0000-0003-2070-215X
Yelena BogdanovaPhysical Medicine & Rehabilitation, VA Boston Healthcare System, 150 South Huntington Avenue, Boston, MA 02130, USA.
Laiene Olabarrieta-LandaHealth Sciences Department, Public University of Navarre (UPNA), Cataluña, s/n, 31006 Pamplona, Spain.ORCID 0000-0002-8305-8720
Elisabet AlzuetaCenter for Health Sciences, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA.ORCID 0000-0002-2770-2104
Fiona C BakerCenter for Health Sciences, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA.
Stella IacovidesSchool of Physiology, Brain Function Research Group, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.
Mar CortesDepartment of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA.ORCID 0000-0003-2828-8504
Juan Carlos Arango-LasprillaDepartments of Psychology and Physical Medicine and Rehabilitation, Virginia Commonwealth University, 907 Floyd Ave, Richmond, VA 23284, USA.ORCID 0000-0002-7184-8311
SRI International · USBoston University · USIcahn School of Medicine at Mount Sinai · USUniversidad Publica de Navarra · ESUniversity of the Basque Country · ESUniversity of the Witwatersrand · ZAUniversity of Virginia · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Some people with COVID-19 develop a series of symptoms that last for several months after infection, known as Long COVID. Although these symptoms interfere with people's daily functioning and quality of life, few studies have focused on neurobehavioral symptoms and the risk factors associated with their development; (2) Methods: 1001 adults from 34 countries who had previously tested positive for COVID-19 completed the Neurobehavioral Symptom Inventory reporting the symptoms before their COVID-19 diagnosis, during the COVID-19 infection, and currently; (3) Results: Participants reported large-sized increases before vs. during COVID-19 in all domains. Participants reported a medium-sized improvement (during COVID-19 vs. now) in somatic symptoms, a small-sized improvement in affective symptoms, and very minor/no improvement in cognitive symptoms. The risk factors for increased neurobehavioral symptoms were: being female/trans, unemployed, younger age, low education, having another chronic health condition, greater COVID-19 severity, greater number of days since the COVID-19 diagnosis, not having received oxygen therapy, and having been hospitalized. Additionally, participants from North America, Europe, and Central Asia reported higher levels of symptoms across all domains relative to Latin America and Sub-Saharan Africa; (4) Conclusions: The results highlight the importance of evaluating and treating neurobehavioral symptoms after COVID-19, especially targeting the higher-risk groups identified. General rehabilitation strategies and evidence-based cognitive rehabilitation are needed in both the acute and Long COVID phases.

Indexed as

COVID-19AdultCOVID-19 TestingFemaleHumansInfant, NewbornMaleOxygenPost-Acute COVID-19 SyndromeQuality of LifeRetrospective StudiesSARS-CoV-2OxygenCOVID-19Long COVIDneurobehavioral symptomsrisk factorsSARS-CoV-2

Identifiers

PMID36231893
PMCPMC9564784
OpenAlexW4303696543

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.